In vitro activity of Alkanna frigida extracts in comparison with glucantime against Leishmania major
,
Abstract
Background and Objectives: Current chemotherapies of cutaneous leihmaniasis have faced to some problems and limitations; Development of new leishmanicidal drugs from different sources like herbal plants, are crucially important. The objective of the present study was evaluation of in vitro activity of Alkanna frigida extracts in comparison with glucantime against Leishmania major.
Materials and Methods: L. major promastigotes were exposed to different concentrations of the A. frigida extracts, processed by ethyl acetate, ethanol, hexane and chloroform. The inhibitory effect, as the IC 50 , were calculated after 24, 48 and 72 hours by linear regression analysis values of the concentrations employed.
Results: The significant inhibition was observed after 24 and 48 hours with different concentrations of compounds (p < 0.05 in all tests). All extracts had potent activity against proliferation of the promastigotes, comparing to the untreated negative control. It could compete with the glucantime efficacy in some concentrations. Ethyl acetate and ethanol extractions showed potent IC value, 106 µg/ml and 86 µg/ml, respectively. Hexane and chloroform extractions had poor efficacy after 24 hours;however, the efficacy increased after 48 and 72 hours.
Conclusion: The results indicated that the A. frigida has appropriate inhibitory effects on the growth of L. major promastigotes in vitro and can be of herbal targets for further investigation in vivo.
Desjeux P. Leishmaniasis: current situation and new perspectives. Clin Dermatol Comp Immunol Microbiol Infect Dis 2004; 27: 305-318.
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012; 7: e35671. doi:10.1371/ journal.pone.0035671.
Saebi E. (2011). Clinical Parasitology: Protozoal Diseases in Iran. 5th ed, (In Persian) Aeeizh, Tehran, Iran.
Yaghoobi-Ershadi MR, Jafari R, Hanafi-Bojd AA. A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med 2004; 24: 98-101.
Fazaeli A, Fouladi B, Sharifi I. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. J Vector Borne Dis 2009; 46:36-42.
Emami MM, Yazdi M, Nilforoushzadeh M. Emergence of cutaneous leishmaniasis due to Leishmania major in a new focus of central Iran. Trans R Soc Trop Med Hyg 2009; 103: 1257-1262.
Razmjou S, Hejazy H, Motazedian MH, Baghaei M, Emamy M, Kalantary M. A new focus of zoonotic cutaneous leishmaniasis in Shiraz, Iran. Trans R Soc Trop Med Hyg 2009; 103: 727-730.
Davami MH, Motazedian MH, Sarkari B. The changing profile of cutaneous leishmaniasis in a focus of the disease in Jahrom district, southern Iran. Ann Trop Med Parasitol ; 2010; 104: 377-382.
Hepburn NC. Cutaneous leishmaniasis. Clin Exp Dermatol 2000; 25: 363-370.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis.
Lancet Infec Dis 2007; 7: 581-596.
Ouellette M, Drummelsmith J, Papadopoulou B.Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Update 2004; 7: 257-266.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-126.
Singh S, Ramu Sivakumar. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004; 10: 307-315.
Alavi-Naini R, Fazaeli A, O’Dempsey T. Topical treat- ment modalities for old world cutaneous leishmaniasis: a review. Prague Medical Report 2012; 113: 105-118.
El-On J, Jacobs GP, Witztum E, Greenblatt CL.Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984; 26: 745-751.
Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ans Aca Med Singapore.2008; 37: 916-918.
Khan MA, Maruno M, Khaskhely NM, Ramzi ST, Hosokawa A, Uezato H, et al. Inhibition of intracellular proliferation of Leishmania parasites in vitro and suppression of skin lesion development in BALB/c mice by a novel lipid A analog (ONO-4007). Am J Trop Med Hyg 2002;67:184-190.
Papageorgiou VP. Wound healing properties of naphthaquinone pigments from Alkanna tinctoria. Experientia 1978; 34:1499-1501.
Papageorgiou VP, Assimopoulou AN, Couladouros EA, Hepworth D, Nicolaou KC. The chemistry and biology of alkannin, shikonin and related naphthazarine natural products. Angew Chem Int Ed 1999; 38: 270-300.
Esfahani HM, Esfahani ZN, Dehaghi NK, Hosseini- Sharifabad A, Tabrizian K, Parsa M. et al. Anti-inflammatory and anti-nociceptive effects of the ethanolic extracts of Alkanna frigida and Alkanna orientalis. J Nat Med 2012; 66: 447-52.
Yazdinezhad A, Monsef-Esfahani HR, Amanzadeh Y, Sadat Ebrahimi SE, Ghahremani MH, Ostad SN. Naphtazarin derivatives from Alkanna frigida. Eur J Sci Res 2009; 27: 29-33.
Harborne JB. (1998). Phytochemical Methods. Chapman & Hall; New York.
Ogurtan Z, Hatipoglu F, Ceylan C. The effect of Alkanna tinctoria Tausch on burn wound healing in rabbits. Dtsch Tiearzt1 Wochenschr 2002; 109: 481-485.
Imami A, Mahmoudi M, Zamani Taghi Zadeh Rabe SH, Ahi A. The investigation of the amount of leishmanicidal in species of Artemisia in vitro. Scientific Journal of Kurdistan University of Medical Sciences (In Prsian) 2008;13: 15-20.
Maspi N, Ghafarifar F, Bahrami AM, Bastaminezhad S, Shamsi M. Evaluation of leishmanicidal effect of watery & ethanolic flowers Calendula officinalis extract on promastigotes of Leishmania major (MRHO/IR 75/ER) in vitro. Journal of Ilam University of Medical Sciences 2000; 1: 28-31.
| Files | ||
| Issue | Vol 5 No 2 (2013) | |
| Section | Articles | |
| Keywords | ||
| Alkanna frigida In vitro activity Leishmania major cutaneous leishmaniasis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
